GFR-话题@MedSci

#GFR#

483篇内容 | 2214人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534659, encodeId=874115346599e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=42, createdTime=2022-09-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534658, encodeId=6267153465802, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Kidney Int：在标准治疗中加入贝利单抗可以降低狼疮肾炎发作和eGFR下降的风险, objectType=article, longId=736854, objectId=0bf6e36854f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bf6e36854f0, replyNumber=0, likeNumber=0, createdTime=2022-08-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bf6e36854f0, moduleTitle=Kidney Int：在标准治疗中加入贝利单抗可以降低狼疮肾炎发作和eGFR下降的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bf6e36854f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534657, encodeId=1af9153465e66, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, objectType=article, longId=736795, objectId=5afee36795cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5afee36795cd, replyNumber=0, likeNumber=43, createdTime=2022-08-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5afee36795cd, moduleTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5afee36795cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534656, encodeId=e45d15346564f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=28, createdTime=2022-08-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534655, encodeId=b55b153465528, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Circulation：射血分数降低的心衰患者应用达格列净后 eGFR 初始下降的发生情况, objectType=article, longId=735957, objectId=7cc4e35957f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cc4e35957f0, replyNumber=0, likeNumber=44, createdTime=2022-08-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cc4e35957f0, moduleTitle=Circulation：射血分数降低的心衰患者应用达格列净后 eGFR 初始下降的发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cc4e35957f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534654, encodeId=e086153465454, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=European Radiology：放射组学实现GGO肺腺癌的EGFR突变状态的无创预测！, objectType=article, longId=735300, objectId=7271e3530013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7271e3530013, replyNumber=0, likeNumber=40, createdTime=2022-08-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7271e3530013, moduleTitle=European Radiology：放射组学实现GGO肺腺癌的EGFR突变状态的无创预测！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7271e3530013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534653, encodeId=93011534653a6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Proteomics Clin Appl：瘢痕疙瘩的新生物标志物：RCN3、CALU、RCN1、PDGFRL, objectType=article, longId=735110, objectId=c2bbe351108b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2bbe351108b, replyNumber=0, likeNumber=51, createdTime=2022-08-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2bbe351108b, moduleTitle=Proteomics Clin Appl：瘢痕疙瘩的新生物标志物：RCN3、CALU、RCN1、PDGFRL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2bbe351108b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534652, encodeId=14711534652f2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, objectType=article, longId=734225, objectId=0acbe3422547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acbe3422547, replyNumber=0, likeNumber=40, createdTime=2022-08-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acbe3422547, moduleTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0acbe3422547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534651, encodeId=6bbc153465185, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展, objectType=article, longId=732985, objectId=b7e9e329851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7e9e329851b, replyNumber=0, likeNumber=35, createdTime=2022-07-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7e9e329851b, moduleTitle=【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7e9e329851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534650, encodeId=91b71534650fe, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势, objectType=article, longId=730863, objectId=42ade3086341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42ade3086341, replyNumber=0, likeNumber=45, createdTime=2022-07-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42ade3086341, moduleTitle=肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42ade3086341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534649, encodeId=8c2c1534649a3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BMC Cancer：奥希替尼治疗EGFR突变的NSCLC合并胸腔积液患者的疗效, objectType=article, longId=729662, objectId=b223e2966237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b223e2966237, replyNumber=0, likeNumber=46, createdTime=2022-06-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b223e2966237, moduleTitle=BMC Cancer：奥希替尼治疗EGFR突变的NSCLC合并胸腔积液患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b223e2966237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534645, encodeId=667015346453f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, objectType=article, longId=729047, objectId=d22fe2904783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22fe2904783, replyNumber=0, likeNumber=39, createdTime=2022-06-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22fe2904783, moduleTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22fe2904783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534647, encodeId=9234153464ef3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA Oncol：EGFR抗体偶联药物MRG003治疗实体肿瘤的安全性和活性, objectType=article, longId=728959, objectId=be9fe2895933, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be9fe2895933, replyNumber=0, likeNumber=52, createdTime=2022-06-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be9fe2895933, moduleTitle=JAMA Oncol：EGFR抗体偶联药物MRG003治疗实体肿瘤的安全性和活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be9fe2895933)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534646, encodeId=cb60153464635, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=34, createdTime=2022-06-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534644, encodeId=1886153464417, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=0, createdTime=2022-06-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534643, encodeId=79ed1534643a4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO2022速递：中国胶质瘤患者EGFR突变的研究概况, objectType=article, longId=728514, objectId=acbee2851469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acbee2851469, replyNumber=0, likeNumber=63, createdTime=2022-06-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acbee2851469, moduleTitle=ASCO2022速递：中国胶质瘤患者EGFR突变的研究概况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acbee2851469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534641, encodeId=7e481534641d4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=肺癌EGFR基因突变治疗失败，应该如何处理？, objectType=article, longId=727993, objectId=d094e27993f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d094e27993f2, replyNumber=0, likeNumber=29, createdTime=2022-05-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d094e27993f2, moduleTitle=肺癌EGFR基因突变治疗失败，应该如何处理？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d094e27993f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534648, encodeId=704215346489b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, objectType=article, longId=727759, objectId=e5e5e27759c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e5e27759c4, replyNumber=0, likeNumber=41, createdTime=2022-05-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e5e27759c4, moduleTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5e5e27759c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534642, encodeId=e12e15346424f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, objectType=article, longId=727709, objectId=f4e9e2770970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4e9e2770970, replyNumber=0, likeNumber=58, createdTime=2022-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4e9e2770970, moduleTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4e9e2770970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534640, encodeId=31a71534640b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=36, createdTime=2022-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2022-09-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Kidney Int：在标准治疗中加入贝利单抗可以降低狼疮肾炎发作和eGFR下降的风险

2022-08-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）

2022-08-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-08-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Circulation：射血分数降低的心衰患者应用达格列净后 eGFR 初始下降的发生情况

2022-08-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

European Radiology：放射组学实现GGO肺腺癌的EGFR突变状态的无创预测！

2022-08-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Proteomics Clin Appl：瘢痕疙瘩的新生物标志物：RCN3、CALU、RCN1、PDGFRL

2022-08-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC

2022-08-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展

2022-07-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势

2022-07-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BMC Cancer：奥希替尼治疗EGFR突变的NSCLC合并胸腔积液患者的疗效

2022-06-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！

2022-06-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA Oncol：EGFR抗体偶联药物MRG003治疗实体肿瘤的安全性和活性

2022-06-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2022-06-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-06-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO2022速递：中国胶质瘤患者EGFR突变的研究概况

2022-06-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

肺癌EGFR基因突变治疗失败，应该如何处理？

2022-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗

2022-05-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法

2022-05-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

科室
- - 订阅+
  - 更多科室
工具
服务